Impact of sodium-glucose cotransporter-2 inhibitors on cardiovascular outcomes in cancer patients: a systematic review and meta-analysis of heart failure hospitalisation and mortality
Abstract
The use of Sodium-glucose cotransporter-2 inhibitors (SGLT2i) has demonstrated cardiovascular benefits in a variety of patient populations [1]. This systematic review and meta-analysis aims to determine the impact of SGLT2i on cardiovascular outcomes, specifically heart failure (HF) hospitalisation and mortality in patients with cancer.
A systematic literature search of PubMed and Ovid databases was conducted from inception until the 18th of November 2023. The search criteria used were : ["((SGLT2) OR (Sodium glucose cotransporter 2 inhibitors) OR (canagliflozin) OR (dapagliflozin) OR (empagliflozin) OR (ertugliflozin)) AND (cancer)"]. The primary inclusion criteria for studies were: Randomised Controlled Trials (RCTs) or observational studies, involving patients administered SGLT2 inhibitors, with a comparison group. The outcomes of interest were all-cause mortality and heart failure hospitalisation. Exclusion criteria included studies not specifically examining patients on SGLT2 inhibitors, and studies not reporting on cardiac dysfunction outcomes. The statistical analysis was conducted using R 4.3.1 on RStudio.
Our search yielded 1304 studies, out of which, 8 studies with 2402 patients receiving SGLT2i and 30,494 controls were included in the analysis. The pooled analysis of 6 studies and 32,197 patients revealed that SGLT2i use was associated with a significant reduction in the risk of All-Cause Mortality (Risk Ratio [RR] 0.49, 95% Confidence Interval [CI] [0.35, 0.67],…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 32,197 participants or records.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.